“…and cancer within neurotumors [15,16], gastroenteric tumors [9,17], genitourinary tumors [18,19], breast carcinoma [20,21], lung carcinoma [10,22], thyroid carcinoma [23], oral squamous-cell cancer [24], myeloid leukemia [25], and cervical cancer [14]. Collectively, the expression of NDRG2 is reduced within human tumors, while its overexpression suppresses the capacity of cancer cells to proliferate, migrate, metabolize and invade [26]; NDRG2 expression levels are negatively correlated with human cancer clinical and pathological conditions [26].…”